Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | SCD | O00767 | 9/20 | 0.44 |
| ▸ | AR | P10275 | 3/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532330 | 0.86 | HRH3 (0.48) | NCF1SCDARSLC2A1CYP3A4 | |
| SCHEMBL5529940 | 0.86 | AR (0.40) | ARKCNH2 | |
| SCHEMBL5527506 | 0.85 | NCF1 (0.43) | NCF1SCDARSLC2A1RBP4 | |
| SCHEMBL5528104 | 0.85 | HRH3 (0.45) | NCF1SCDARSLC2A1CYP3A4 | |
| SCHEMBL5529926 | 0.84 | NCF1 (0.44) | NCF1SCDARSLC2A1PDE10A | |
| SCHEMBL8235688 | 0.84 | AR (0.39) | ARCYP3A4 | |
| SCHEMBL5532313 | 0.82 | NCF1 (0.42) | NCF1SCDARSLC2A1KCNH2 | |
| SCHEMBL5530620 | 0.82 | KCNH2 (0.41) | SCDSLC2A1RBP4KCNH2HRH3 | |
| SCHEMBL5530874 | 0.81 | SCD (0.43) | NCF1SCDARCYP3A4CYP2D6 | |
| SCHEMBL5527453 | 0.81 | NCF1 (0.41) | NCF1SCDARSLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | NCF1 2805/4885SCD 1710/4885AR 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.